Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.44) by 77.27 percent. This is a 70.59 percent increase over losses of $(0.34) per share from the same period last year.
Pfizer Gets FDA Breakthrough Therapy Designation For GBS Vaccine Candidate
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE: PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy.
